Explain the diagnostic criteria for Major Neurocognitive Disorder Due to Traumatic Brain Injury.

Explain the diagnostic criteria for Major Neurocognitive Disorder Due to Traumatic Brain Injury.

Explain the evidenced-based psychotherapy and psychopharmacologic treatment for Major Neurocognitive Disorder Due to Traumatic Brain Injury.

Identify the risks of different types of therapy and explain how the benefits of the therapy that might be achieved might outweigh the risks. Support your rationale with references to the Learning Resources or other academic resource.

Week 8: Neurocognitive Disorders

Discussion: Treatment of Major Neurocognitive Disorder Due to Traumatic Brain Injury

Post:

Explain the diagnostic criteria for Major Neurocognitive Disorder Due to Traumatic Brain Injury.

Explain the evidenced-based psychotherapy and psychopharmacologic treatment for Major Neurocognitive Disorder Due to Traumatic Brain Injury.

Identify the risks of different types of therapy and explain how the benefits of the therapy that might be achieved might outweigh the risks. Support your rationale with references to the Learning Resources or other academic resource.

Learning Resources

Required Readings

Sadock, B. J., Sadock, V. A., & Ruiz, P. (2014). Kaplan & Sadock’s synopsis of psychiatry: Behavioral sciences/clinical psychiatry (11th ed.). Philadelphia, PA: Wolters Kluwer.

· Chapter 21, “Neurocognitive Disorders” (pp. 694–741)

Gabbard, G. O. (2014). Gabbard’s treatment of psychiatric disorders (5th ed.). Washington, DC: American Psychiatric Publications.

· Chapter 63, “Delirium”

· Chapter 64, “Neurocognitive Disorder Due to Alzheimer’s Disease”

· Chapter 65, “Front temporal Neurocognitive Disorder”

· Chapter 66, “Vascular Neurocognitive Disorder”

· Chapter 67, “Neurocognitive Disorder Due to Parkinson’s Disease”

Note: You will access this textbook from the Walden Library databases.

American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Washington, DC: Author.

· “Neurocognitive Disorders”

Note: You will access this book from the Walden Library databases.

Stahl, S. M. (2014). Prescriber’s Guide: Stahl’s Essential Psychopharmacology (5th ed.). New York, NY: Cambridge University Press.

 

Note: All Stahl resources can be accessed through the Walden Library using the link below. This link will take you to a login page for the Walden Library. Once you log in to the library, the Stahl website will appear. http://ezp.waldenulibrary.org/login?url=http://stahlonline.cambridge.org/

 

To access information on specific medications, click on The Prescriber’s Guide, 5th Ed. tab on the Stahl Online website and select the appropriate medication.

 

Alzheimer disease	Delirium	Dementia	Parkinson’s disease dementia
caprylidene donepezil galantamine memantine rivastigmine	haloperidol (adjunct) lorazepam (adjunct)	donepezil galantamine memantine rivastigmine	rivastigmine pimavanserin

Note: For more information on Pimavanserin, see:

Acadia Pharmaceuticals. (2017). Transform the treatment of Parkinson’s disease psychosis with NUPLAZID. Retrieved from https://www.nuplazidhcp.com/?gclid=CIHS5auvwtMCFQkaaQodrU0FGQ

U.S. Food and Drug Administration. (n. d.). Highlights of prescribing information: Nuplazid. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207318lbl.pdf

Hopkins, S. A., & Chan, D. (2016). Key emerging issues in frontotemporal dementia. Journal of Neurology, 263(2), 407–413. doi:10.1007/s00415-015-7880-7

 

Note: You will access this article from the Walden Library databases.

Walker, Z., Possin, K. L., Boeve, B. F., & Aarsland, D. (2015). Lewy body dementias. The Lancet, 386(10004), 1683-1697.

 

Note: You will access this article from the Walden Library databases.

Laureate Education (Producer). (2017a). A gentleman with a neurocognitive disorder [Multimedia file]. Baltimore, MD: Author.

 

Bolin, P. (2015, December 31). Neurocognitive disorders – CRASH! Medical review series [Video file]. Retrieved from https://www.youtube.com/watch?v=bQXOPITY9XM

 

Note: The approximate length of this media piece is 57 minutes.

Optional Resources

Kota, L. N., Bharath, S., Purushottam, M., Moily, N. S., Sivakumar, P. T., Varghese, M., . . . Jain, S. (2015). Reduced telomere length in neurodegenerative disorders may suggest shared biology. The Journal of Neuropsychiatry and Clinical Neurosciences, 27(2), e92–e96. doi:10.1176/appi.neuropsych.13100240

Lepkowsky, C. M. (2016). Neurocognitive disorder with Lewy bodies: Evidence-based diagnosis and treatment. Practice Innovations, 1(4), 234–242. doi:10.1037/pri0000031

Oltra-Cucarella, J., Pérez-Elvira, R., Espert, R., & Sohn McCormick, A. (2016). Are cognitive interventions effective in Alzheimer’s disease? A controlled meta-analysis of the effects of bias. Neuropsychology, 30(5), 631–652. doi:10.1037/neu0000283